Table 3.

Tumor Response of Different PD-(L)1 Inhibitor Groups

PD-(L)1 Inhibitor	CR	PR	SD	PD	P
Santolina	2 (16.7%)	6 (50.0%)	4 (33.3%)	0 (0%)	0.683
Tislelizumab	2 (28.6%)	1 (14.3%)	3 (42.8%)	1 (14.3%)
Tropaia	4 (23.5%)	6 (35.3%)	6 (35.3%)	1 (5.9%)
Camrelizumab	3 (10.7%)	14 (50.0%)	10 (35.7%)	1 (3.6%)

Notes: Data were presented as n (%) or mean ± standard deviation.

Abbreviations: CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.